PCA3 and cancer: In the prospective cohort, out of 1,790 patients in the Gleason groups 4&5, 763 (42%) have low PCA3. These results confirmed high levels of PCA3 was a poor predictor of high grade disease and low PCA3 levels was not an indication of the absence of cancer.